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Abstract 
Context: Trichosanthin produced in the root tube of Trichosanthes kirilowii shows anti-tumor activity on a series of 
cancer cells including Hela, MCF-7, HL-60. But there is little information about its effect on the carcinogenesis of pros-
tate cancer.
Objective: This work was designed to study the role of trichosanthin on prostate cancer cells PC3.
Materials and methods: Trichosanthin was expressed in BL21 strain and purified by affinity chromatography. MTT 
assay was designed to determine the effect of trichosanthin on growth of PC3 cells at doses of 10, 20, 40, 60, 80, and 
120 μg/ml. Then the effect of 50 μg/ml rTCS alone or combined with 2 μM IL-2 on PC3 cell proliferation was analyzed. 
And the mechanism of rTCS was studied by western blot. After that the in vivo effect of rTCS combined with IL-2 was 
explored in mice bearing PC3 xenograft tumor.
Results: Trichosanthin was successfully expressed in BL21 and purified by 100 mM imidazole. It was shown to inhibit 
proliferation of PC3 cells in a dose-dependent manner with IC50 50.6 μg/ml. When combined with cytokine IL-2, a 
significant synergic effect was obtained. The inhibition rate on PC3 was around 50 % in combination group while only 
35.5 % in single rTCS group at 50 μg/ml. Further, the expression of full length caspase-8 and Bcl-2 decreased signifi-
cantly while cleaved caspase-8 and Bax were up-regulated, which suggest that caspase-8-mediated apoptosis path-
way may be activated by rTCS in PC3 cells. Moreover, our data demonstrated that tumor volume and tumor weight 
were significantly reduced in rTCS-treated or rTCS/IL-2-treated nude mice bearing PC3 xenograft tumor compared 
with control. And significant difference was also found between rTCS and rTCS/IL-2 group.
Conclusions: This study demonstrates that rTCS is a potential agent with high in vitro and in vivo anti-tumor activity 
on PC3 cells. And rTCS combined with IL-2 is a promising strategy in treating patients with prostate cancer in future.
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Background
Trichosanthin (TCS), extracted from the root tube of Tri-
chosanthes kirilowii, is a single-chain protein which could 
inhibit protein synthesis by hydrolyzing N–C glycosidic 
bond of eukaryotic ribosome 28S rRNA [1]. TCS was 
used as an abortifacient drug to treat hydatidiform moles, 
invasive moles, and ectopic pregnancy [2, 3]. Empirical 
studies have attributed these effects to trichosanthin 
(hereafter referred to as RTCS), a 27-kDa protein puri-
fied from T. kirilowii tubers. TCS was reported to have 
immune-regulatory activity. It could ablate the replica-
tion of human immunodeficiency virus (HIV) and herpes 
simplex virus type 1 (HSV-1) [4, 5]. TCS is a potential 
antidote against some tumors as it could suppress the 
tumor cell growth in different ways. First, it can pro-
duce reactive oxygen species (ROS) and initiate apopto-
sis in human chorio-carcinoma (Jar) cells [6, 7]. Second, 
TCS can induce the death of human cervical carcinoma 
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(Hela) cells by increasing cytosolic calcium accompanied 
with the suppression of cAMP/protein kinase C level [8, 
9]. Third, the apoptosis-inducing activity of TCS applies 
to mouse NIH 3T3 embryonic fibroblasts by the activa-
tion of caspase-8 and caspase-3 pathways [10]. Fourth, 
TCS can induce apoptosis of human lung cancer cells by 
G1 phase arrest, anti-telomerase effects, and inhibition 
of cell migration and metastasis [11, 12], Furthermore, 
TCS was shown to elicit apoptosis of human HL-60 cells 
through caspase-3-mediated pathway [13, 14].
Prostate cancer is one of the most common diseases for 
men and remains a leading cause of death in most devel-
oped countries, especially for old men [15, 16]. Among 
all men diagnosed with cancer with age of over 70 years, 
about 50  % were prostate cancer. Although localized 
prostate cancer could be removed by surgery and radia-
tion therapy, about 30–50 % patients would have a local 
or distant recurrence. So it is urgent to develop more 
potent drug or effective strategy to treat prostate can-
cer. IL-2 is a well-known molecule with activity of sup-
pressing tumor cell growth [17, 18]. And IL-2 has been 
successfully applied in treating a series of tumor cells in 
combination with other agent [19, 20].
In this study, we found that recombinant trichosanthin 
(rTCS) could significantly inhibit proliferation of pros-
tate cancer cells PC3 both in vitro and in vivo. And IL-2 
could obviously enhance the inhibitory effect of rTCS on 
PC3 cell. Additionally, the caspase8-mediated apopto-
sis pathway was shown activated in PC3 cell. Our work 
broadened the medicinal applications of rTCS and the 
combination of rTCS with IL-2 serves as a novel strategy 
against human prostate cancer.
Methods
Cell lines and reagents
Cell line PC3 was a gift from Prof. Hedy and cultured in 
RPMI-1640 medium with 10 % fetal bovine serum (Inv-
itrogen Co., USA) containing 100  μg/mL penicillin and 
100  U/mL streptomycin (Biotech Biology Company). 
IL-2 was purchased from Bioscience Company. Ni Sepha-
rose 6 Fast Flow was from GE healthcare (USA). Restric-
tion enzymes (NdeI and NheI), Pfu DNA polymerase and 
T4 DNA ligase were purchased from Takara Biotech Co., 
Ltd. (Dalian, China).
Construction of plasmid pET22b‑rTCS
The primers PF and PR for rTCS was designed and added 
with NdeI and NheI restriction enzyme sites (Table  1). 
rTCS gene was amplified from plasmids pbs-rTCS 
preserved in our laboratory. The DNA fragment was 
digested with restriction enzymes, and cloned between 
NdeI and NheI sites of pMD18T-rTCS. The rTCS gene 
was confirmed by DNA sequencing. The PET22b vector 
and the rTCS gene were ligated by T4 ligase. The resulted 
plasmid, named PET22b-rTCS, was transformed into E. 
coli BL21(DE3) (TIANGEN Biotech Co., Ltd, China) fol-
lowing the standard procedure.
Expression and purification of recombinant rTCS
Overnight culture of E. coli BL21 (DE3) cells from a sin-
gle colony were inoculated at ratio of 1 % (volume) into 
Luria–Bertani medium, and then grown at 37 °C for 3 h. 
IPTG was added to a final concentration of 0.4  mM at 
25  °C for 8  h of induction until the medium was 0.6–
0.8 of OD600. Cells were collected by centrifugation at 
3500 rpm for 10 min, and then suspended in 50 ml cold 
lysis buffer and disrupted by sonication. The cell lysates 
were then centrifuged at 13,000 rpm for 10 min at 4 °C. 
The supernatant and pellet were subjected to a 12  % 
sodium dodecyl sulfate–polyacrylamide gel electropho-
resis (SDS-PAGE). In brief, they were mixed with equal 
volume of 2  ×  SDS sample loading buffer and water 
respectively. After boiled for 5  min each sample was 
separated by 12 % separating gel. The gel was run at con-
stant voltage of 120 V. After electrophoresis, SDS-PAGE 
gels were stained with Coomssie Brilliant Blue G-250.
Lysates were clarified by centrifugation and allowed 
to bind to nickel affinity resin for 1 h at 4  °Cwith gentle 
mixing. After being washed with lysis buffer, the rTCS 
protein was eluted with elution buffer solution (about 
100  mM imidazole). The elution fractions were purified 
by nickel column with automated protein separation 
chromatography system.
Western blot analysis of recombinant rTCS
Five microgram per millilitre protein was separated on 
10 % SDS–polyacrylamide gel electrophoresis, and trans-
ferred to polyvinylidene fluoride (PVDF) membranes. 
Then the transferred PVDF was blocked at room temper-
ature for 2 h in 5 % (w/v) nonfat milk in TBST (20 mM 
Tris–HCl, pH 7.6, 500 mM NaCl, 0.1 % Tween 20), and 
incubated overnight at 4 °C with the primary antibody in 
TBST buffer with 1 % (w/v) bovine serum albumin. After 
that PVDF was incubated with anti-trichosanthin anti-
body (Santa Cruz, USA). After washing with TBST, the 
membranes were incubated with goat-anti-mouse sec-
ondary antibodies (1:200) and determined with the ECL 
kit (Pierce Biotechnology, Rockford, IL, USA) according 
to the manufacturer’s instructions.
Table 1 Primers used for amplification of TCS
Primer Sequence 5‑3 Enzyme site added
Forward cCATATGatgatcagattcttagtcctc NdeI
Reverse gGCTAGCctaaatagcataacttcca NheI
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Cell proliferation assay
The PC3 cells were seeded into 96-well microtiter plates at 
1 × 104 cells/well and incubated for 24 h. After treatment 
with various concentrations of recombinant rTCS (10, 20, 
40, 60, 80, 120 μg/ml) and rTCS (50 μg/ml) +IL-2 (2 µM) 
for 48 h, cell viability assays were performed using the MTT 
method. MTT dissolved in PBS was added to the cultures 
at a final concentration of 0.5 µg/ml. After further incuba-
tion at 37  °C for 4  h, the medium was carefully removed 
and formazan crystals were dissolved in 150 μl DMSO per 
well, and the absorbance at 490 nm was measured on a pla
te reader with DMSO as a blank control. The cell inhi-
bition rate was calculated as follow:
Data was analyzed from three independent 
experiments.
In vivo xenograft studies
Eighteen female BALB/c nude mice (7  weeks old, 25  g) 
were obtained from the Model Animal Research Center 
of Nanjing University and procedures of all animal experi-
ments were approved by the Nanjing University Animal 
Research Ethics Committee. The xenograft model was 
constructed as follows: 1 × 107 PC3 cells in 200 μL RPMI 
1640 medium were injected subcutaneously into the right 
flanks of mice. Once the tumors were about 100  mm3, 
mice were randomly divided into three groups (six mice 
per group). One group was treated with an intraperitoneal 
injection of rTCS at a dose of 5.0 mg/kg/day for 10 days. 
The other group was treated with rTCS (5.0  mg/kg/
day) + IL-2 (1 mg/kg/day). In the control group, the same 
volume of PBS was administered. Tumor diameters were 
serially recorded with an electronic caliper every 2  days, 
and tumor volume was calculated with the formula:
Tumor body weight was weighed after mice were sacri-
ficed on the 15th day.
Statistical analysis
The IC50 value was calculated by SPSS11.0 software. All 
the data are shown in mean standard deviation (S.D.) 
from three independent experiments. Student t test was 
applied for the comparison between two groups. P value 
less than 0.05 was considered statistically significant.
Results
The expression and purification of rTCS protein
As shown in Fig. 1a, the coding sequence for rTCS was 
amplified and correctly cloned into expression vector 
Inhibition rate (IR) = (A490 of untreated samples
− A490 of treated samples)
/A490 of untreated samples× 100%.
tumor volume (mm3) = 0.5× length × width2
pET22b. Then rTCS protein was expressed and puri-
fied as stated above. The optimized condition for rTCS 
expression was 4  h after induction with 0.4  mM IPTG 
(Fig.  1b). And 100  mM imidazole was used to purify 
rTCS (Fig.  1c). Western blot analysis with anti-rTCS 
monoclonal antibody further proved the band was rTCS 
(Fig.  1d). And as reported in early research, rTCS here 
was about 27.5 KDa.
rTCS inhibited proliferation of PC3 cells
rTCS was reported to inhibit growth of several kinds of 
tumor cells including Hela, HL-60, lung cancer cells in 
early research. We demonstrated that rTCS could also 
suppress the growth of prostate cancer cells PC3. As 
shown in Fig. 2a, the growth of PC3 cells was significantly 
inhibited in rTCS-treated group compared to control. 
And this effect was dose dependent which was in con-
sistent with the results on breast cancer cells MCF-7. 
The IC50 was about 50.6  µg/ml. IL-2 was a well-known 
cytokine with activity of suppressing tumor cell growth. 
And IL-2 has been successfully applied in clinic to treat 
a series of tumors. In this study, we proved that IL-2 
could obviously enhance the inhibitory effect of rTCS on 
PC3 cell. As in Fig. 2b, the inhibition rate of PC3 cell in 
rTCS/IL-2-treated group was about 50 % while it was only 
35.5  % in rTCS-treated group alone, which suggest that 
there is an obvious synergic effect between rTCS and IL-2.
Fig. 1 The expression and purification of rTCS. a PCR amplification 
of CDS for rTCS. Lane 1 stands for the CDS coding rTCS. b Expression 
of rTCS in BL21 E. coli. Lane 1 to lane 3 stands for the control, clone 
1, clone 2 respectively. c Purified rTCS by affinity adsorption. Lane 1 
stands for purified rTCS. D. Western blot analysis of rTCS with anti-TCS 
antibody. Lane 1 and lane 2 stand for the same sample
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rTCS activated caspase‑8‑mediated apoptosis in PC3 cells
Evading apoptosis is a typical character for tumor cells. 
And one mechanism for many therapeutic drugs was 
to induce tumor cell apoptosis by caspase-8-regulated 
plasma membrane extrinsic pathway or caspase-9-regu-
lated cell damage intrinsic pathway. As shown in Fig. 2c, 
the expression of full length pro-caspase-8 decreased 
dramatically after treated with 20 or 60 μg/ml rTCS for 
24  h compared to control. And the anti-apoptosis mol-
ecule Bcl-2 decreased too. But cleaved caspase-8 and 
Bax was up-regulated significantly after 24 h. These data 
demonstrated that rTCS activated caspase-8-mediated 
apoptosis pathway in PC3 cells.
rTCS suppressed tumor growth in nude mice
Similar to in vitro assay, in vivo data indicated that rTCS 
could suppress growth of PC3 xenograft tumor. The nude 
mice bearing PC3 xenograft tumor was treated with 
rTCS (5 mg/kg body weight, i.p. once a day for 10 days) 
alone or combined with IL-2 (1 mg/kg body weight, i.p. 
once a day for 10 days). As shown in Fig. 3, on the tenth 
day, the tumor volume showed an obvious reduction 
compared with control. On the 15th day, mice were sac-
rificed and tumor weight decreased significantly in both 
rTCS group (100 ± 22 versus 40 ± 13 mg) and rTCS/IL-2 
group (100 ± 22 versus 22 ± 10 mg) compared with con-
trol. Also there was significant difference between rTCS-
treated group and rTCS/IL-2-treated group.
Discussion
Prostate cancer ranks as one of the most common and 
severe cancer in men with increasing incidence as well 
as high risk of metastasis and relapse. Medicinal plants 
are rich sources of biologically active natural products 
for drug development. It was reported that trichosanthin 
regulated immune responses and induced apoptosis in 
Fig. 2 rTCS inhibits proliferation and induces apoptosis of PC3 cells. a A series of concentration of rTCS including 10, 20, 40, 60, 80, 120 ug/ml was 
used to treat PC3 cells. And rTCS was shown to inhibit proliferation of PC3 cells in a dose-dependent manner. b 50 µg/ml rTCS was combined with 
2 μM IL-2 to treat PC3 cells. The inhibitory rate in combinatory group was about 50 % while it was only 35.5 % in 50 µg/ml rTCS single group. c rTCS 
activates caspase-8-mediated apoptosis. The level of full length caspase-8 and Bcl-2 decreased significantly in 20 or 60 µg/ml rTCS-treated group 
after 24 h. But the level of cleaved caspase-8 as well as Bax dramatically increased. Statistical analysis of data was performed with t-test, and *P<0.05 
indicated a statistically significant difference
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several kinds of tumor cells. However, its effects on pros-
tate cancer are rarely studied. Prostate cancer is the most 
common malignancy for men worldwide. In the United 
States, there were an estimated 220,800 new cases of 
prostate cancer and 27,540 deaths in 2015, representing 
26 % of new cancer cases and 9 % of male cancer death 
[21]. This makes prostate cancer the second leading cause 
of cancer death in men. Although the disease can poten-
tially be cured when localized, metastatic prostate cancer 
remains incurable. Treatment of localized prostate can-
cer is usually based on surgery and/or radiation therapy. 
However, even after definitive local therapy, approxi-
mately 30–50  % of patients will have a local or distant 
recurrence. Patients with metastatic prostate cancer only 
have a median survival of 3–7  years followed by death 
[22]. Treatment options for these men are limited and 
do not improve overall survival [23]. Novel therapies for 
these patients are urgently needed.
In recent years, scientists are trying to develop new 
drugs and new therapeutic strategy for prostate can-
cer. Immune-based therapy against cancer is extensively 
studied. The accelerated understanding of molecular 
mechanisms underlying prostate cancer growth and 
spread fueled the hope fighting against prostate cancer.
Translational and laboratory-based clinical investiga-
tions of novel drugs are in progress. The 27-kDa tricho-
santhin is a ribosome inactivating protein extracted from 
tubers of the Chinese herbal plant Trichosanthes kirilowii 
Maximowicz [24, 25]. In this study, rTCS obtained by 
gene-engineering technology showed significant inhibi-
tory effect on PC3 cells growth. We also indicated that 
rTCS potentially activated caspase-8-regulatory pathway 
and induced apoptosis of PC3 cells, which was in consist-
ent with early research [26]. Moreover, rTCS could sig-
nificantly reduce the PC3 xenograft tumor weight and 
tumor volume in nude mice.
Nowadays combination therapy in animal model as 
well as in preclinical experiments holds a promising 
strategy [27, 28]. Interleukin IL-2 is an immune-regula-
tory cytokine [29, 30] and has been applied in clinical to 
treat a series of diseases [31, 32]. Here IL-2 was shown 
to improve the anti-proliferation effect of rTCS on PC3 
cells. A significant synergic effect between rTCS and IL-2 
was demonstrated in vitro and in vivo. The combination 
therapy strategy between IL-2 and rTCS may bring new 
hope for patients with prostate cancer.
Conclusion
Trichosanthin was successfully expressed and purified in 
this study. The recombinant trichosanthin was shown to 
inhibit growth of prostate cancer cells PC3 both in vitro 
and in  vivo. The caspase-8 mediated apoptosis pathway 
was shown to be activated by the recombinant trichosan-
thin. Moreover, trichosanthin was demonstrated to func-
tion synergically with interleukin-2 to inhibit the growth 
of PC3 cells. Our data provides a promising hope for clin-
ical application of rTCS/IL-2 in future.
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